Why capillary electrophoresis still matters in modern biopharma by Roxana McCloskey | Jun 9, 2026 | Biopharma, Blogs, CEExplore why capillary electrophoresis remains essential for high resolution, confident analytics across modern biopharma modalities, from proteins to mRNA and gene therapies
Where does capillary electrophoresis fit across drug development? by Roxana McCloskey | Jun 9, 2026 | Biopharma, Blogs, CECapillary electrophoresis (CE) is not confined to a single point in the drug development lifecycle. Its value comes from the ability to deliver high‑resolution, reproducible separations that remain relevant as analytical questions evolve, from early discovery through late‑stage development and lot release.
Why middle‑down and subunit MS analyses powered by EAD are transforming biopharmaceutical characterization by Roxana McCloskey | May 15, 2026 | Biopharma, BlogsAs an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
Why electron-activated dissociation (EAD) improves sequence variant analysis in biopharma LC/MS workflows by Roxana McCloskey | Apr 29, 2026 | Biopharma, BlogsIn biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
How NFD improves impurity detection and peak integration in CE SDS workflows by Roxana McCloskey | Apr 28, 2026 | Biopharma, BioPhase 8800 system, BlogsCE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
CE‑SDS in monoclonal antibody therapeutic development by Roxana McCloskey | Mar 31, 2026 | Biopharma, BioPhase 8800 system, BlogsIn monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
Predictable uptime starts with a predictable service strategy by Andrea Mueller | Mar 18, 2026 | Biopharma, Blogs, Clinical, Environmental / Industrial, Food / Beverage, Forensic, Life Science Research, Pharma, Service, Support, TechnologyIn analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Advancing bioanalysis with SCIEX: Insights from three decades of innovation by Kirsten Craven | Feb 18, 2026 | Biopharma, Blogs, PharmaFor decades, SCIEX has been part of bioanalytical innovation, empowering scientists in pharma and biopharma to push the boundaries of sensitivity, accuracy, and throughput. Across complex workflows and increasingly challenging therapeutic modalities.
From downtime to confidence: Why OEM support can make a difference by Gary Chambers | Dec 5, 2025 | Biopharma, Blogs, Clinical, Environmental / Industrial, Food / Beverage, Forensic, Life Science Research, Pharma, Service, Support, TechnologyIn today’s environment in which labs are under pressure to reduce operating costs, many will compare the cost of a service contract between third-party providers and the original equipment manufacturer (OEM). At first glance, going with a service contract from a third-party provider may seem like a smart financial move, but experience shows they can introduce risks that affect reliability and compliance.
Your success and voice go a long way! by Andrea Mueller | Oct 1, 2025 | Biopharma, Blogs, Clinical, Environmental / Industrial, Food / Beverage, Forensic, Life Science Research, Pharma, TechnologyAt the heart of everything we do is ensuring that your workflows and team are empowered to achieve optimal results with your SCIEX instruments, software, consumables, and services. Every interaction with SCIEX is designed to support your success through the dedication...